within Pharmacolibrary.Drugs.ATC.A;

model A07AA11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.01,
    Cl             = 0.00018333333333333334,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.007,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0023000000000000004,
    Tlag           = 16.200000000000003
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A07AA11</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Rifaximin is a poorly absorbed, gut-selective antibiotic belonging to the rifamycin family. It is used for the treatment of travelers' diarrhea caused by noninvasive strains of Escherichia coli, reduction in risk of hepatic encephalopathy recurrence, and irritable bowel syndrome with diarrhea (IBS-D). It is approved and commonly prescribed for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters measured in healthy adult volunteers following single and multiple oral dosing of 400 mg rifaximin.</p><h4>References</h4><ol><li><p>Trapnell, CB, et al., &amp; Bettenhausen, DK (2007). Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. <i>The Annals of pharmacotherapy</i> 41(2) 222–228. DOI:<a href=&quot;https://doi.org/10.1345/aph.1H395&quot;>10.1345/aph.1H395</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17284510/&quot;>https://pubmed.ncbi.nlm.nih.gov/17284510</a></p></li><li><p>Pentikis, HS, et al., &amp; Bettenhausen, DK (2007). The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. <i>Pharmacotherapy</i> 27(10) 1361–1369. DOI:<a href=&quot;https://doi.org/10.1592/phco.27.10.1361&quot;>10.1592/phco.27.10.1361</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17896891/&quot;>https://pubmed.ncbi.nlm.nih.gov/17896891</a></p></li><li><p>Taylor, DN, et al., &amp; Bourgeois, AL (2008). Systemic pharmacokinetics of rifaximin in volunteers with shigellosis. <i>Antimicrobial agents and chemotherapy</i> 52(3) 1179–1181. DOI:<a href=&quot;https://doi.org/10.1128/AAC.01108-07&quot;>10.1128/AAC.01108-07</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18086855/&quot;>https://pubmed.ncbi.nlm.nih.gov/18086855</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A07AA11;
